Foghorn Therapeutics Q1 revenue falls to $3.3 million; net loss widens to $19.9 million
Foghorn Therapeutics reported first-quarter 2026 results, with collaboration revenue down to $3.3 million from $6.0 million a year earlier and a net loss of $19.9 million, up from $18.8 million. Net loss per share was $0.29, versus $0.30 a year earlier, on a larger share count of 69,540,075 weighted average shares. The company said it had $183.6 million in cash, cash equivalents and marketable securities, which it expects to fund operations into the first half of 2028.
Key points
- Collaboration revenue was $3.3 million for the quarter ended March 31, 2026, down $2.7 million from $6.0 million, due to the timing of work under the Lilly Collaboration Agreement.
- Net loss was $19.9 million, compared with $18.8 million a year earlier; research and development expenses fell to $18.3 million from $21.6 million.
- Net loss per share was $0.29, compared with $0.30 a year earlier.
- Cash, cash equivalents and marketable securities were $183.6 million as of March 31, 2026, with cash runway into the first half of 2028.
The filing
Written by AI on Nov 9, 2026, 11:43 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on May 07, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.